Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127127 | 0.89 | NPC1 (0.53) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL27865356 | 0.87 | TSHR (0.58) | TSHRNPC1KMT2ALMNAMAPT | |
| Propylene Oxide SCHEMBL27807203 | 0.87 | BCHE (0.43) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL27301503 | 0.84 | MEN1 (0.47) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL101601 | 0.83 | TSHR (0.63) | TSHRNPC1RAB9AKMT2ALMNA | |
| SCHEMBL29702037 | 0.83 | TSHR (0.63) | TSHRNPC1RAB9AKMT2ALMNA | |
| SCHEMBL23231964 | 0.82 | ALDH1A1 (0.58) | NPC1RAB9AKMT2AMAPTHPGD | |
| SCHEMBL15768394 | 0.82 | TSHR (0.55) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7629352 | 0.82 | NPC1 (0.47) | TSHRNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL13355960 | 0.82 | NPC1 (0.47) | TSHRNPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | claimed |
| CN-116096765-B | Curable composition | 株式会社LG化学 | 2024-12-13 | — | — | CN | disclosed |
| CN-117940522-A | Curable composition, protective film, optical element, and liquid crystal display device | 株式会社LG化学 | 2024-04-26 | — | — | CN | disclosed |
| CN-114409630-B | Pharmaceutical compositions comprising oxoisoindole compounds and methods of using the same | 细胞基因公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116745295-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-110869021-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116096765-A | Curable composition | 株式会社LG化学 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022255400-A1 | CLEANER FOR INDOOR WATER USE SITES | 住友化学株式会社 | 2022-12-08 | — | — | WO | disclosed |
| CN-114404596-A | Antiproliferative compounds and second agents for the treatment of multiple myeloma | 细胞基因公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114409630-A | Pharmaceutical compositions comprising oxoisoindole compounds and methods of using the same | 细胞基因公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-2766336-A1 | PROCESS FOR PREPARING ALKOXY ARYL ESTER | Saudi Basic Industries Corporation (SA) | 2014-08-20 | — | — | EP | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013053455-A1 | PROCESS FOR PREPARING ALKOXY ARYL ESTER | SAUDI BASIC INDUSTRIES CORPORATION (SABIC) (SA) | 2013-04-18 | — | — | WO | disclosed |
| EP-1846395-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK'S AND GSK'S | Astex Therapeutics Limited (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| CN-1128783-C | Process for distillation of crude ester in DMT/PTA process | DEGUSSA (DE) | 2003-11-26 | — | — | CN | disclosed |
| US-5859143-A | BLOCK COPOLYMERIZATION REACTION IN PRESENCE OF HYDROGEN AND STEREOSPECIFIC CATALYST CONTAINING COMPOUNDS OF MAGNESIUM, TITANIUM, HALOGEN, ORGANOALUMINUM AND ELECTRON DONOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 1999-01-12 | — | — | US | disclosed |
| CN-1176847-A | Catalyst and method for catalytic off-gas cleaning in DMT process | HUELS CHEMISCHE WERKE AG (DE) | 1998-03-25 | — | — | CN | disclosed |
| CN-1172101-A | Process for distillation of crude ester in DMT/PTA process | HUELS CHEMISCHE WERKE AG (DE) | 1998-02-04 | — | — | CN | disclosed |
| US-4542189-A | Process for the preparation of novel rubber-modified thermoplastic resin compositions using multiple feed streams | THE STANDARD OIL COMPANY (US) | 1985-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | TSHR 4310/4885NPC1 3613/4885RAB9A 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.